C-peptide reduces pro-inflammatory cytokine secretion in LPS-stimulated U937 monocytes in condition of hyperglycemia

[1]  M. Trucco,et al.  C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells , 2011, Diabetologia.

[2]  R. Robertson.  Update on transplanting beta cells for reversing type 1 diabetes. , 2010, Endocrinology and metabolism clinics of North America.

[3]  S. Ball,et al.  Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein , 2010, Diabetologia.

[4]  M. Hollenberg,et al.  Insulin Modulates Protease-Activated Receptor 2 Signaling: Implications for the Innate Immune Response , 2010, The Journal of Immunology.

[5]  A. Secchi,et al.  Impact of pancreas transplantation on type 1 diabetes-related complications , 2010, Current opinion in organ transplantation.

[6]  S. Devaraj,et al.  Diabetes is a proinflammatory state: a translational perspective , 2010, Expert review of endocrinology & metabolism.

[7]  G. Cavaletti,et al.  Regression of diabetic complications by islet transplantation in the rat , 2009, Diabetologia.

[8]  P. Drain,et al.  C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes , 2009, Diabetologia.

[9]  G. Bruno,et al.  Fasting Plasma C-Peptide and Micro- and Macrovascular Complications in a Large Clinic-Based Cohort of Type 1 Diabetic Patients , 2009, Diabetes Care.

[10]  M. Trucco,et al.  Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells. , 2008, Atherosclerosis.

[11]  G. Warnock,et al.  Reduced Progression of Diabetic Retinopathy After Islet Cell Transplantation Compared With Intensive Medical Therapy , 2008, Transplantation.

[12]  H. Tse,et al.  Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-κB pathway , 2008, Diabetologia.

[13]  R. Flores,et al.  Sustained IL‐1α, IL‐4, and IL‐6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus , 2008, Pediatric diabetes.

[14]  A. Cheung,et al.  Evidence of Increased Inflammation and Microcirculatory Abnormalities in Patients With Type 1 Diabetes and Their Role in Microvascular Complications , 2007, Diabetes.

[15]  Y. Naito,et al.  Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. , 2007, Atherosclerosis.

[16]  G. Piraino,et al.  Proinsulin c-peptide exerts beneficial effects in endotoxic shock in mice , 2007, Critical care medicine.

[17]  D. Becker,et al.  Increased Expression of Monocyte CD11b (Mac-1) in Overweight Recent-Onset Type 1 Diabetic Children. , 2007, The review of diabetic studies : RDS.

[18]  P. Dandona,et al.  Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose. , 2006, Seminars in thoracic and cardiovascular surgery.

[19]  S. Bustin,et al.  Altered Monocyte Cyclooxygenase Response to Lipopolysaccharide in Type 1 Diabetes , 2006, Diabetes.

[20]  S. Griffen,et al.  Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. , 2006, Diabetes.

[21]  P. Libby,et al.  Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. , 2005, Circulation.

[22]  C. Stehouwer,et al.  Plasma Levels of AGE Peptides in Type 1 Diabetic Patients Are Associated with Serum Creatinine and Not with Albumin Excretion Rate: Possible Role of AGE Peptide‐Associated Endothelial Dysfunction , 2005, Annals of the New York Academy of Sciences.

[23]  A. Sima,et al.  The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. , 2005, Diabetes.

[24]  N. Brunskill,et al.  Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. , 2004, The Journal of biological chemistry.

[25]  A. Sima,et al.  Effects of C-peptide on expression of eNOS and iNOS in human cavernosal smooth muscle cells. , 2004, Urology.

[26]  J. Piganelli,et al.  Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. , 2004, Free radical biology & medicine.

[27]  B. Zuckerbraun,et al.  Overexpression of mutated IκBα inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation , 2003 .

[28]  A. Sima,et al.  C‐peptide enhances insulin‐mediated cell growth and protection against high glucose–induced apoptosis in SH‐SY5Y cells , 2003, Diabetes/metabolism research and reviews.

[29]  C. Forsblom,et al.  Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients , 2003, Diabetologia.

[30]  N. Chaturvedi,et al.  Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. , 2003, Diabetes care.

[31]  G. Van den Berghe,et al.  Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. , 2003, The Journal of clinical endocrinology and metabolism.

[32]  B. Zuckerbraun,et al.  Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation. , 2003, Journal of Vascular Surgery.

[33]  Å. Lernmark,et al.  Macrophages from High‐Risk HLA‐DQB1*0201/*0302 Type 1 Diabetes Mellitus Patients are Hypersensitive to Lipopolysaccharide Stimulation , 2002, Scandinavian journal of immunology.

[34]  J. Lambeth,et al.  The neutrophil NADPH oxidase. , 2002, Archives of biochemistry and biophysics.

[35]  M. Tarakçıoğlu,et al.  Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. , 2001, Clinical biochemistry.

[36]  A. M. Lefer,et al.  C‐peptide inhibits leukocyte‐endothelium interaction in the microcirculation during acute endothelial dysfunction , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  A. M. Lefer,et al.  C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. , 2000, American journal of physiology. Heart and circulatory physiology.

[38]  J. Wahren,et al.  Beneficial effects of C‐peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[39]  A. Hutson,et al.  Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. , 1999, The Journal of clinical investigation.

[40]  T. Ogihara,et al.  In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.

[41]  P. Baeuerle,et al.  Role of nuclear factor‐kappa B in atherogenesis , 1997, Experimental physiology.

[42]  J. Assal,et al.  [Long-term complications in diabetes mellitus]. , 1989, Acta medica portuguesa.

[43]  D. Baltimore,et al.  I kappa B: a specific inhibitor of the NF-kappa B transcription factor. , 1988, Science.